Hans Lilja
18Patents
9h-index
21Co-inventors
72Inventor score
Filing activity: Mar 19, 1993 → Feb 27, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6265540A | Tissue specific prodrug | Human Necessities | 44 | Expired |
| US5501983A | Assay of free and complexed prostate-specific antigen | Physics | 31 | Expired |
| US5939533A | Assay of free and complexed prostate-specific antigen (PSA) | Physics | 21 | Expired |
| US5614372A | Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1) | Emerging Cross-Sectional Technologies | 20 | Expired |
| US7053042B1 | Activation of peptide prodrugs by hK2 | Chemistry; Metallurgy | 16 | Expired |
| US6504014B1 | Tissue specific prodrug | Human Necessities | 16 | Expired |
| US7872104B2 | Antibody, immunoassay and method for prostate cancer detection | Physics | 11 | Expired |
| US9672329B2 | Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume | Physics | 10 | Active |
| US6410514B1 | Tissue specific prodrug | Human Necessities | 9 | Expired |
| US6143509A | Prostate specific antigen peptides and uses thereof | Emerging Cross-Sectional Technologies | 5 | Expired |
| US7906477B2 | Activation of peptide prodrugs by hK2 | Human Necessities | 3 | Active |
| US5912158A | Prostate specific antigen (PSA)-proteinase inhibitor complexes | Physics | 2 | Expired |
| US12131802B2 | Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume | Physics | 1 | Active |
| US11761962B2 | Compositions and methods related to diagnosis of prostate cancer | Emerging Cross-Sectional Technologies | 1 | Active |
| US10672503B2 | Methods and apparatuses for conducting analyses | Physics | 1 | Active |
| US8450280B2 | Activation of peptide prodrugs by hK2 | Chemistry; Metallurgy | 0 | Active |
| US8669231B2 | Activation of peptide prodrugs by hK2 | Human Necessities | 0 | Active |
| US12326453B2 | Compositions and methods for active surveillance of prostate cancer | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.